No. 19-1475

Duke University v. Biomarin Pharmaceutical Inc.

Lower Court: Federal Circuit
Docketed: 2020-07-08
Status: Denied
Type: Paid
Experienced Counsel
Tags: 35-usc-314 administrative-law administrative-patent-judges appointments-clause due-process forfeiture inter-partes-review patent patent-law standing statutory-interpretation
Key Terms:
DueProcess Patent Trademark Privacy JusticiabilityDoctri
Latest Conference: 2020-11-06
Question Presented (AI Summary)

Whether a court of appeals can invoke forfeiture to refuse to address an Appointments Clause violation in a pending appeal despite an intervening change in law

Question Presented (from Petition)

QUESTIONS PRESENTED In enacting the Leahy-Smith America Invents Act, Pub. L. No. 112-29, § 6(a), 125 Stat. 284, 299 (2011) (“AIA”), Congress created a powerful new mechanism for challenging patents called “inter partes review.” Cuozzo Speed Techs., LLC v. Lee, 136 S. Ct. 2131, 2136 (2016). Relying on this new procedure, a panel of the Patent Trial and Appeal Board, consisting of three administrative patent judges, revoked Duke’s patent claims despite unrebutted evidence of a long-felt but unsolved need, failure of others, industry praise, and commercial success. While Duke’s case was pending on appeal, the Federal Circuit decided in another case, Arthrex, Inc. v. Smith & Nephew, Inc. 941 F.3d 1320 (Fed. Cir. 2019), reh’g denied, 953 F.3d 760 (2020) (en banc), that the administrative patent judges who conduct inter partes reviews hold office in violation of the Appointments Clause. The Federal Circuit has repeatedly refused to apply that ruling to cases like this one where the appellant did not challenge the appointments in its opening brief on appeal. The questions presented are: 1. Whether a court of appeals can invoke forfeiture to refuse to address an Appointments Clause violation in a pending appeal despite an intervening change in law. 2. Whether the U.S. Patent and Trademark Office Director’s delegation of authority to institute inter partes reviews to administrative patent judges acting i as principal officers outside the Director’s review violates 35 U.S.C. § 314, which vests institution authority solely in the Director. 3. Whether establishing a nexus between a patentee’s invention and objective evidence of nonobviousness under Graham v. John Deere Co., 383 U.S. 1 (1966), requires the patentee to negate every other conceivable reason for a product’s commercial success and industry praise.

Docket Entries

2020-11-09
Petition DENIED.
2020-10-21
DISTRIBUTED for Conference of 11/6/2020.
2020-10-19
Reply of petitioner Duke University filed. (Distributed)
2020-10-06
Brief of respondent BioMarin Pharmaceutical, Inc. in opposition filed.
2020-07-29
Motion to extend the time to file a response is granted and the time is extended to and including October 6, 2020.
2020-07-21
Motion to extend the time to file a response from August 7, 2020 to October 6, 2020, submitted to The Clerk.
2020-07-02
Petition for a writ of certiorari filed. (Response due August 7, 2020)

Attorneys

BioMarin Pharmaceutical, Inc.
Gerald Myers Murphy Jr.Birch, Stewart Kolasch & Birch, LLP, Respondent
Gerald Myers Murphy Jr.Birch, Stewart Kolasch & Birch, LLP, Respondent
Gerald M. Murphy Jr.Birch Stewart Kolasch Birch, LLP, Respondent
Gerald M. Murphy Jr.Birch Stewart Kolasch Birch, LLP, Respondent
Duke University
Steven Alan ZalesinPatterson Belknap Webb and Tyler LLP, Petitioner
Steven Alan ZalesinPatterson Belknap Webb and Tyler LLP, Petitioner